COVID-19 Convalescent Plasma Shows Early Survival Benefit
Researchers assessed the efficacy of the COVID-19 convalescent plasma in offering survival benefit at 7 and 14 days for patients hospitalized with the disease.
Patricia Chaney
Patricia Chaney is a freelance writer specializing in the healthcare industry. She has 15 years of experience writing for providers, patients and other healthcare stakeholders. Her work has appeared on numerous health system websites and in industry journals.
